Finzati - Logo
RVPH logo

Reviva Pharmaceuticals Holdings, Inc.

RVPH • Biotechnology
$0.43
▼ -0.02 (-4.44%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$6.46M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.05Healthy liquidity · 2.08Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:39 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.43
Change-4.44%
Market Cap$6.46M
52W Range0.26 - 17.20
Beta0.49
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.05
Current Ratio2.08
Quick Ratio2.08
Volume22.00K

Investment DNA

How strong this company looks for long-term investors

46
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
84/100
Why this score▼
Manageable debt level · 0.05Healthy liquidity · 2.08Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 12/15/2020
Industry: Biotechnology
P/B i: 2.34
Debt / Equity i: 0.05
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.05
Current Ratio: 2.08
Quick Ratio: 2.08
Status: Good

Insider Transactions

Recent executive and insider activity

Bhat Laxminarayan
Transaction: 03/18/2026
BUY
Change
+40,925
Price
$1.87
Filing
03/20/2026
Type
BUY
Prabhu Narayan
Transaction: 03/18/2026
BUY
Change
+40,925
Price
$1.87
Filing
03/20/2026
Type
BUY
SAXENA PARAG
Transaction: 12/18/2025
BUY
Change
+8,200
Price
$0.58
Filing
12/19/2025
Type
BUY